Cellartis AB, a premier provider of stem cell derived products and technologies, today announced that the company is to be acquired by the French biotech corporation Cellectis S.A.

Cellartis AB was founded 2001 in Göteborg, Sweden, as a university spin-off and has developed a world-leading stem cell platform and products based on human pluripotent stem cells. This acquisition will merge over ten years of stem cell innovation from Cellartis with world leading genome engineering capabilities from Cellectis. The new organization will be uniquely placed to deliver truly innovative products, services, and collaborative opportunities aiming towards cutting edge drug discovery and toxicology platforms as well as regenerative medicine applications.

"We are extremely delighted to take the next transformative steps and continue to build on our stem cell platform together with Cellectis" said Johan Hyllner, CEO of Cellartis. "In my opinion, the deal represents a giant leap forward in creating a strong industrial corporation, encompassing many new innovations and entering the stem cell and regenerative medicine arena."

"We are enthusiastic to have the opportunity to combine Cellartis' world-renowned expertise in pluripotent stem cells-based industrial applications with Cellectis' highend genetic engineering platform. Together, we will be in a position to accelerate the development of stem cell based solutions including therapies targeting diseases reputed as incurable thanks to regenerative medicine", underlines Gunnar Fernström, Chairman of Cellartis, adding he is "convinced that the industrial platform and the stem cell- based products developed by Cellartis during the last decade are very valuable assets which will significantly contribute to the creation of a world leader in stem cells."

"The acquisition of Cellartis demonstrates our will to accelerate our development via targeted, relevant external growth operations" declares André Choulika, co-Founder, Chairman and CEO of Cellectis. "At Cellectis, we are very pleased to continue to build on Cellartis' unique stem cell platform in synergy with our genome editing technology."

In return for the full divestment of their stake, Cellartis shareholders will receive 16.4 million euro in cash and 1.93 million Cellectis shares.

Danske Bank Corporate Finance and Advokatfirman Vinge are acting as advisors to Cellartis and its owners on this transaction.

www.cellartis.com
www.cellectis.com